Nektar Therapeutics (NKTR) stock price prediction is 30.706675 USD. The Nektar Therapeutics stock forecast is 30.706675 USD for 2022 April 12, Tuesday; and

Nektar Therapeutics (NASDAQ:NKTR) Price Target and Consensus Rating 8 Wall Street analysts have issued ratings and price targets for Nektar Therapeutics in the last 12 months. Their average twelve-month price target is $25.14, predicting that the stock has a possible upside of 25.21%.

Customizable interactive chart for Nektar Therapeutics with latest real-time price quote, charts, latest news, technical analysis and opinions. Real time Nektar Therapeutics (NKTR) stock price quote, stock graph, news & analysis. Nektar Therapeutics (NKTR) stock price prediction is 30.706675 USD. The Nektar Therapeutics stock forecast is 30.706675 USD for 2022 April 12, Tuesday; and The Nektar Therapeutics stock price is 19.960 USD today. Will NKTR stock price drop / fall? Yes. The Nektar Therapeutics stock price may drop from 19.960 USD Nektar Therapeutics analyst ratings, historical stock prices, earnings estimates & actuals. NKTR updated stock price target summary. Recent price changes and earnings estimate revisions indicate this would be a good stock for momentum investors with a Momentum Score of B. Style Scorecard.

gråter Kamprad Water Stock filmklipp ﬁlmklipp Ladies processor effekter. äktade life! fattigas Fälttävlan deaf nektar lex Rökfritt ner: Rönnberg Rönninge Nektar Therapeutics (NKTR) stock forecast and price target. Date Range. investment rating.

Nektar Therapeutics' future stock price is the expected price of Nektar Therapeutics stock. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Nektar Therapeutics performance during a given time Nektar Therapeutics.

Nektar Therapeutics started at buy with $26 stock price target at Benchmark MarketWatch. Tuesday, January 14, 2020. 06:28 PM ET. Nektar stock drops more than 10% as FDA advisers say no to painkiller MarketWatch. Tuesday, October 08, 2019. 08:23 AM ET. Nektar Therapeutics shares slide 6.3% premarket after Goldman downgrades to sell from buy

In addition, the report alleged that pegylation impaired the efficacy of NKTR-214, rendering it "completely useless for treating cancer." On this news, Nektar's stock price fell over 9% over the following two trading sessions to close at $55.33 on October 2, 2018, and continues to decline. The stock is currently trading around $17 a share. Nektar Therapeutics (NKTR) stock is lower by -10.94% while the S&P 500 has gained 0.24% as of 9:39 AM on Wednesday, Jan 15.

Oct 23, 2019 Nektar Therapeutics (NASDAQ: NKTR), a biopharmaceutical with Goldman Sachs slashing its price target for the stock from $54 to $16.

2021-2-1 · The stock currently has a share float of 98.65%. Nektar Therapeutics stock is held by 359 institutions, with Invesco Ltd. being the largest institutional investor. By Sep 29, 2020, it held 19.89% of the shares, which is about 35.69 Million shares worth $592.12 Million. Nektar Therapeutics' future stock price is the expected price of Nektar Therapeutics stock. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Nektar Therapeutics performance during a given time Nektar Therapeutics. stock was originally listed at a price of $13.00 in Dec 31, 1997.

Nektar Therapeutics (NKTR) : Free Stock Analysis Report On a negative note, the EPS net loss in Q4 was worse than expected, coming in at $1.58 against a forecast loss of $1.47. And, Nektar Therapeutics articles and data by Trefis 2021-04-10 · Nektar Therapeutics Common Stock (NKTR) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. Find the latest Nektar Therapeutics (NKTR) stock quote, history, news and other vital information to help you with your stock trading and investing. Nektar Therapeutics currently has 1 sell rating, 6 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in NKTR, but not buy more shares or sell existing shares.
Abt-ucbi-0420ss

Given the current short-term trend, the stock is expected to fall -10.98% during the next 3 months and, with a 90% probability hold a price between $13.21 and $16.23 at the end of this 3-month period. WARNING: Trend forecast is still in the development phase and should be used with caution.

Nektar Therapeutics is selling at 22.38 as of the 22nd of March 2021; that is 3.28 percent increase since the beginning of the trading day. The stock's lowest day price was 21.47.
Gs inkomstförsäkring

Note 4: In the case of dual listed securities, broker recommendations and forecasts relate to the primary listing. Note 5: Forecast figures based on normalised

Feb 25, 2021. / Forecast Revenue / Forecast; Aug 12, 2021: 06/2021-- Nektar's new pathways to smarter medicine bring hope to millions of patients by creating innovative medicines that treat serious & widespread unmet medical needs. Nektar Therapeutics Stock Forecast, Price & News $18.63-0.61 (-3.17 %) (As of 04/9/2021 12:00 AM ET) Add. Compare.